Round Table Discussion: The Statistician's View on Outcome Methodologies for Pharmacologic Trials in Mild, Moderate, and Severe Alzheimer's Disease

Abstract

John Lyons: I just organized my thoughts on essentially three different domains. If you are pursuing clinical trials, particularly in severely demented individuals, there are three different sets of domains that I believe might be reasonable to think about, and all of these have been touched on today.